HIT Technologies Inc. Closes Private Placement of Debentures and Common Shares

VANCOUVER, BC—(Marketwired – October 31, 2016) – HIT Technologies Inc. (the “Company”) (TSX VENTURE: HIT) is pleased to announce that it closed its non–brokered private placement (the “Debenture Offering”) of secured convertible debentures (the “Debentures”), raising aggregate gross proceeds to the Company of $375,000.

At the closing of the Debenture Offering, the Company issued Debentures in the principal amount of $375,000 (the “Debenture Sum”). The Debentures will expire on October 31, 2018 (the “Maturity Date”). The Debenture Sum will bear interest at a rate of 10% per annum and may be converted, in whole or in part, at the sole discretion of the subscribers, at any time prior to the Maturity Date, into common shares in the capital of the Company (“Conversion Shares”). The conversion rate will be one Conversion Share for each $0.05 of the Debenture Sum, if any portion of the Debenture Sum is converted within 12 months from the issue date, and one Conversion Share for each $0.10 of the Debenture Sum, if any portion of the Debenture Sum is converted after 12 months from the issue date. The Debentures, as well as any Conversion Shares issued upon conversion of the Debenture Sum, will be subject to a four–month hold period which will expire on March 1, 2017.

The Company is also pleased to announce that it closed its non–brokered private placement (the “Common Share Offering” and together with the Debenture Offering, the “Offerings”) of common shares in the capital of the Company (the “Common Shares”), raising aggregate gross proceeds to the Company of $90,000.

At the closing of the Common Share Offering, the Company issued an aggregate of 1,800,000 Common Shares at a subscription price of $0.05 per Common Share. The Common Shares will be subject to a four–month hold period which will expire on March 1, 2017.

The Company received conditional acceptance of the Offerings from the TSX Venture Exchange. The net proceeds of the Offerings will be used by the Company for developing the Company's products, including cases and accessories for the current and next generation Apple iPhone and for general working capital purposes.

About HIT Technologies Inc.

The Company develops and markets a portfolio of products that transform Apple iPhones into high–performing, weather– and shock–resistant video cameras. Both of its flagship products, HITCASE PRO and its newer SNAP, allow users to easily capture action photo and video content hands–free, using a variety of the Company's patented Railslide™ mounts that attach to virtually any surface. Swappable lenses and accessories provide a variety of perspectives otherwise unattainable while participating in adventure sports. The Company is headquartered in Vancouver, British Columbia, Canada and trades on the TSX Venture Exchange (TSX VENTURE: HIT). For more information about HITCASE, visit www.HITCASE.com. Search #hitcase on Instagram to see some of the amazing images created by HITCASE customers.

Cautionary Statement

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this press release.

This press release may contain forward–looking statements within the meaning of applicable securities laws. Forward–looking statements may include estimates, plans, anticipations, expectations, opinions, forecasts, projections, guidance or other similar statements that are not statements of fact. Although the Company believes that the expectations reflected in such forward–looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are subject to certain risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, and may be based on assumptions that could cause actual results to differ materially from those anticipated or implied in the forward–looking statements. The Company's forward–looking statements are expressly qualified in their entirety by this cautionary statement. The forward–looking statements contained in this press release are made as of the date hereof and the Company undertakes no obligations to update publicly or revise any forward–looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Myovant Raises $218 Million in Largest Biotech IPO of Year

PALO ALTO, CA—(Marketwired – October 31, 2016) – Cooley advised Myovant Sciences on its $218 million initial public offering – the largest biotech IPO of the year. The company now trades on the New York Stock Exchange under the symbol “MYOV.”

Myovant, a Cooley client since its formation, is a biopharmaceutical company focused on the innovative treatment of women's health diseases and other endocrine–related disorders in areas of high unmet medical need, and improving the lives of millions of patients suffering from these diseases.

In addition to advising on the company's formation, Cooley advised on Myovant's exclusive license from Takeda Pharmaceuticals of the drug candidates that were the basis of Myovant's launch. Takeda granted Myovant exclusive, worldwide licenses (excluding Japan and certain other Asian countries) to two drug candidates – relugolix (TAK–385), a phase 3 drug candidate that has successfully demonstrated significant clinical benefit for uterine fibroids, endometriosis and prostate cancer, and RVT–602 (TAK–448), a novel product candidate for the treatment of infertility in females.

In June 2015, Cooley advised Axovant Sciences on its $362 million IPO, reportedly the largest pre–commercial stage biotech IPO to date. Axovant and Myovant are majority owned subsidiaries of Roivant Sciences.

The Cooley corporate securities team advising Myovant was led by partners Frank Rahmani and John McKenna and included associates Alison Haggerty and Jason Saxe. The licensing team included partners Barbara Kosacz and Marya Postner and special counsel Marjorie Wagman. Support for the offering was provided by partners Greg Tenhoff (employment), Barbara Mirza (compensation and benefits) and Natasha Leskovsek (health care and life sciences regulatory).

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high–stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.